Open AccessINTERLEUKIN (IL) 12, IL-23 AND IL-23 RECEPTOR IN ANKYLOSING SPONDYLITIS PATHOPHYSIOLOGY
Author(s) -
Marius Cherciu,
Laura Ioana Cherciu,
Mihai Bojincă,
Teodora Şerban,
C. Bara,
Otilia Popa
Publication year - 2015
Publication title -
romanian journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2069-6086
pISSN - 1843-0791
DOI - 10.37897/rjr.2015.1.1
Subject(s) - ankylosing spondylitis , receptor , pathophysiology , immunology , interleukin , interleukin 10 , single nucleotide polymorphism , medicine , biology , gene , cytokine , genetics , genotype
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis which involves mainly the spine and the sacroiliac joints, but also the peripheral joints and non-articular structures. IL-12 and IL-23 are heterodimeric cytokines sharing a common p40 subunit. Studies showed than IL-12 is essential for Th1 differentiation while IL-23 promotes a particular subset of T cells characterized by IL-17 production, called Th17. Since the association of IL-23R with AS was reported, the scientific interest has focused on identifying new single nucleotide polymorphisms (SNPs), present in the coding genes for IL-12/IL-23 subunits and their receptors, that increase the susceptibility for AS. Another point of interest for researchers was to investigate if the identified gene variants modify the gene expression of the respective interleukins and/or their receptors, whether that refers to their mRNA expression, their serum levels or the expression of the receptors on the surface of T cells. Given the increasing amount of data that suggests the pivotal role of the IL-23/Th17 axis in AS pathophysiology, new promising therapies, designed to interfere with these pathways, are now in development.